Alex Thompson
Stock Analyst at Stifel
(1.63)
# 3,149
Out of 4,874 analysts
36
Total ratings
46.43%
Success rate
-8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.74 | +184.24% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $45.71 | +20.32% | 1 | May 20, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $15.12 | +52.12% | 3 | May 2, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Hold | $23 → $5 | $5.45 | -8.17% | 2 | Mar 28, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $4.68 | +669.23% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $29.99 | +100.07% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $173.17 | +19.54% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $11.63 | +321.32% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $560.04 | -10.72% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $16.03 | +236.87% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $44 | $18.13 | +142.69% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.45 | -18.37% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $47.33 | +45.78% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.56 | -35.90% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $14.55 | +174.91% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $9.73 | +3,188.80% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $16.39 | +107.44% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.30 | +2,448.26% | 1 | Dec 14, 2022 |
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.74
Upside: +184.24%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $45.71
Upside: +20.32%
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $15.12
Upside: +52.12%
Third Harmonic Bio
Mar 28, 2025
Downgrades: Hold
Price Target: $23 → $5
Current: $5.45
Upside: -8.17%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $4.68
Upside: +669.23%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $29.99
Upside: +100.07%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $173.17
Upside: +19.54%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $11.63
Upside: +321.32%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $560.04
Upside: -10.72%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $16.03
Upside: +236.87%
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $18.13
Upside: +142.69%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.45
Upside: -18.37%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $47.33
Upside: +45.78%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.56
Upside: -35.90%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $14.55
Upside: +174.91%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $9.73
Upside: +3,188.80%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $16.39
Upside: +107.44%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.30
Upside: +2,448.26%